State-of-the-art approaches to sentinel node biopsy for breast cancer: Study design, patient selection, technique, and quality control at Memorial Sloan-Kettering Cancer Center

Surgical Oncology

Volumn 8, Issue 2, 1999, Pages 85-91

  Cody III, Hiram S ^a   Borgen, Patrick I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYE;

BIOPSY TECHNIQUE; BREAST BIOPSY; BREAST CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW;

EID: 0033500675     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(99)00029-8     Document Type: Article

References (33)

1. Morton D.L., Wen D.R., Wong J.H.et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 127:1992;392-399.
2. Krag D.N., Weaver D.L., Alex J.C., Fairbank J.T. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 2:1993;335-340.
3. Giuliano A.E., Kirgan D.M., Guenther J.M., Morton D.L. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 220:1994;391-401.
4. Albertini J.J., Lyman G.H., Cox C.et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 276:1996;1818-1822.
5. Veronesi U., Paganelli G., Galimberti V.et al. Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 349:1997;1864-1867.
6. Pijpers R., Hoekstra O.S., Collet G.J.et al. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer. J Nucl Med. 38:1997;366-368.
7. Roumen R.M.H., Valkenburg J.G.M., Geuskens L.M. Lymphoscintigraphy and feasibility of sentinel node biopsy in 83 patients with primary breast cancer. Eur J Surg Oncol. 23:1997;495-502.
8. Galimberti V., Zurrida S., Zucali P., Luini A. Can sentinel node biopsy avoid axillary dissection in clinically node-negative breast cancer patients? The Breast. 7:1998;8-10.
9. Borgstein P.J., Pijpers R., Comans E.F., van Diest P.J., Boom R.P., Meijer S. Sentinel lymph node biopsy in breast cancer. guidelines and pitfalls of lymphoscintigraphy and gamma probe detection J Am Coll Surg. 186:1998;275-283.
10. Krag D.N., Ashikaga T., Harlow S.P., Weaver D.L. Development of sentinel node targeting technique in breast cancer patients. The Breast Journal. 4:1998;67-74.
11. Offodile R., Hoh C., Barsky S.H.et al. Minimally invasive breast cancer staging using lymphatic mapping with radiolabeled dextran. Cancer. 82:1998;1704-1708.
12. Krag D., Weaver D., Ashikaga T.et al. The sentinel node in breast cancer - a multicenter validation study. New Engl J Med. 339:1998;941-946.
13. Crossin J.A., Johnson A.C., Stewart P.B., Turner W.W. Gamma-probe-guided resection of the sentinel lymph node in breast cancer. American Surgeon. 64:1998;666-669.
14. Snider H., Dowlatshahi K., Fan M., Bridger W.M., Rayudu G., Oleske D. Sentinel node biopsy in the staging of breast cancer. Am J Surg. 176:1998;305-310.
15. Veronesi U., Paganelli G., Viale G.et al. Sentinel lymph node biopsy and axillary dissection in breast cancer. results in a large series J Natl Cancer Inst. 91:1999;368-373.
16. Giuliano A.E., Jones R.C., Brennan M., Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 15:1997;2345-2350.
17. Guenther J.M., Krishnamoorthy M., Tan L.R. Sentinel lymphadenectomy for breast cancer in a community managed care setting. Cancer J Sci Am. 3:1997;336-340.
18. Flett M.M., Going J.J., Stanton P.D., Cooke T.G. Sentinel node localization in patients with breast cancer. Br J Surg. 85:1998;991-993.
19. Borgstein P.J., Meijer S., Pijpers R. Intradermal blue dye to identify sentinel lymphnode in breast cancer. Lancet. 349:1997;1668-1669.
20. O'Hea B.J., Hill A.D.K., El-Shirbiny A.et al. Sentinel lymph node biopsy in breast cancer. initial experience at Memorial Sloan-Kettering Cancer Center J Am Coll Surg. 186:1998;423-427.
21. Barnwell J.M., Arredondo M.A., Kollmorgen D.et al. Sentinel node biopsy in breast cancer. Ann Surg Oncol. 5:1998;126-130.
22. Hill A.D.K., Tran K.N., Akhurst T.et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg. 229:1999;528-535.
23. Ollila D.W., Giuliano A.E. Intraoperative lymphatic mapping and sentinel lymphadenectomy using isosulfan blue dye. Breast Diseases. 8:1998;297-300.
24. Liberman L, Cody HS, Hill ADK, et al. Sentinel lymph node biopsy after percutaneous diagnosis of nonpalpable breast cancer. Radiology 1999 (in press):
25. Linehan D.C., Hill A.D.K., Tran K.N.et al. Sentinel lymph node localization in breast cancer. unfiltered isotope is superior to filtered J Am Coll Surg. 188:1999;377-381.
26. Linehan DC, Hill ADK, Akhurst T, Tran KN, Borgen PI, Cody HS. Intradermal radiocolloid and intraparenchymal blue dye injection optimizes sentinel node identification in breast cancer patients. Ann Surg Oncol 1999 (in press).
27. Cody H.S., Urban J.A. Internal mammary node status. a major prognosticator in axillary node-negative breast cancer Ann Surg Oncol. 2:1995;32-37.
28. Veronesi U., Cascinelli N., Bufalino R. Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg. 198:1983;681-684.
29. Veronesi U., Cascinelli N., Greco M. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg. 202:1985;702-707.
30. Bares R., Muller B., Fass J., Buell U., Schumpelick V. The radiation dose to surgical personnel during intraoperative radioimmunoscintimetry. Eur J Nucl Med. 19:1992;110-112.
31. Miner T.J., Shriver C.D., Flicek P.R.et al. Guidelines for the safe use of radioactive materials during localization and resection of the sentinel lymph node. Ann Surg Oncol. 6:1999;75-82.
32. Gershenwald J.E., Colome M.I., Lee J.E.et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 16:1998;2253-2260.
33. Cody H.S., Hill A.D.K., Tran K.N., Brennan M.F., Borgen P.I. Credentialing for breast lymphatic mapping - how many cases are enough? Ann Surg. 229:1999;723-728.